ENGLISH
CBS2017
Previous Next
Home < 科学研究

搜索结果

数量：1763 条

排序

Refine search

2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with)

Guideline | By J Brugada, DG Katritsis, ESC Scientific Document Group et al.

Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function

Consensus | By Mazzolai L, Aboyans V, Ageno W et al.

Complete Revascularization with Multivessel PCI for Myocardial Infarction

Clinical Trial | By Mehta SR, Wood DA, COMPLETE Trial Steering Committee and Investigators.

BACKGROUND - In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear.   METHODS - We randomly assigned patients with STEMI and multivessel coronary artery disease who ha...

1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction

Clinical Trial | By GN Janssens, NW van der Hoeven, JS Lemkes et al.

OBJECTIVES- The aim of the present study was to determine the effect of a delayed versus an immediate invasive approach on final infarct size and clinical outcome up to 1 year.   BACKGROUND- Up to 24% of patients with acute coronary syndromes present with ST-segment elevation myocardial infarction (STEMI) but show complete resolution of ST-segment elevation and symptoms before revascularization. Cu...

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI

Clinical Trial | By DMF Claassens, GJA Vos, TO Bergmeijer et al.

BACKGROUND - It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors.   METHODS - We conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with stent implantation were assigned in a 1:1 ratio to receive either a P2Y12 inhibitor on the basis of early CYP2...

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Clinical Trial | By Schüpke S, Neumann FJ, ISAR-REACT 5 Trial Investigators.

BACKGROUND - The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. METHODS - In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. The primary end point...

EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update

Consensus | By Glikson M, Wolff R, Hindricks G et al.

Chapter 1. Background and pathophysiology of thrombus formation in the left atrium The rationale for the quest to close the left atrial appendage (LAA) for stroke prevention is composed of three elements: the concept that atrial fibrillation (AF) causes strokes, the concept that strokes are associated with thrombus formation in the LAA, and that these thrombi cause strokes by embolisation to the cerebral circulation. There are strong d...

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Clinical Trial | By P Vranckx, M Valgimigli, A Goette et al.

BACKGROUND - We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI).   METHODS - ENTRUST-AF PCI was a randomised, multicentre, open-label, non-inferiority phase 3b trial with masked outcome evaluation, done at 186 sites in 18 countries. Patients had atrial fibrillation requiring oral anticoa...

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Clinical Trial | By Oldgren J, Steg PG, Hohnloser SH et al.

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Clinical Trial | By SD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,

BACKGROUND - The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor–neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.   METHODS - We randomly assigned 482...

By Article Type

Original Research 785
Review Article 294
Clinical Case Study 28
Clinical Trial 415
Perspective 9
Guideline 50

By Year

2019 9
2018 1

By Journal

N Engl J Med. 4
Lancet. 1
JACC Cardiovasc Interv. 1
EuroIntervention. 1
Eur Heart J. 1
Eur Heart J. 2

Limit By

Title
Content
|<<... 103 104 105 106 107 108 109 ...>>|
↑BACK TO TOP

左主干暨冠状动脉分叉病变峰会

南京市心血管医院丨南京市第一医院丨南京医科大学

长乐路68号丨210006丨中国 · 南京

Copyright ⓒ CBSMD Nanjing China. All rights reserved.

关于境内代表注册有疑问请联系彭红娟、徐海梅老师

+86 - 139 138 954 77 丨 +86 - 139 147 368 46 丨 cbsnj@cbsmd.org

关于境外代表注册有疑问请联系林玲老师

+86 - 139 518 845 96 丨 cbsnj@cbsmd.org

关于学术征集有疑问请联系赵莹莹女士

+86 138 154 085 17 丨 sub@cbsmd.org